Literature DB >> 22927559

Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries.

Nadia Aissaoui1, Etienne Puymirat, Xavier Tabone, Bernard Charbonnier, Francois Schiele, Thierry Lefèvre, Eric Durand, Didier Blanchard, Tabassome Simon, Jean-Pierre Cambou, Nicolas Danchin.   

Abstract

AIM: The historical evolution of incidence and outcome of cardiogenic shock (CS) in acute myocardial infarction (AMI) patients is debated. This study compared outcomes in AMI patients from 1995 to 2005, according to the presence of CS. METHOD AND
RESULTS: Three nationwide French registries were conducted 5 years apart, using a similar methodology in consecutive patients admitted over a 1-month period. All 7531 AMI patients presenting ≤48 h of symptom onset were included. The evolution of mortality was compared in the 486 patients with CS vs. those without CS. The incidence of CS tended to decrease over time (6.9% in 1995; 5.7% in 2005, P = 0.07). Thirty-day mortality was considerably higher in CS patients (60.9 vs. 5.2%). Over the 10-year period, mortality decreased for both patients with (70-51%, P = 0.003) and without CS (9-4%, P < 0.001). In CS patients, the use of percutaneous coronary intervention (PCI) increased from 20 to 50% (P < 0.001). Time period was an independent predictor of early mortality in CS patients (OR for death, 2005 vs. 1995 = 0.45; 95% CI: 0.27-0.75, P = 0.005), along with age, diabetes, and smoking status. When added to the multivariate model, PCI was associated with decreased mortality (OR = 0.38; 95% CI: 0.24-0.58, P < 0.001). In propensity-score-matched cohorts, CS patients with PCI had a significantly higher survival.
CONCLUSIONS: Cardiogenic shock remains a clinical concern, although early mortality has decreased. Improved survival is concomitant with a broader use of PCI and recommended medications at the acute stage. Beyond the acute stage, however, 1-year survival has remained unchanged.

Entities:  

Mesh:

Year:  2012        PMID: 22927559     DOI: 10.1093/eurheartj/ehs264

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  51 in total

1.  Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy.

Authors:  Christian Jung; Georg Fuernau; Suzanne de Waha; Ingo Eitel; Steffen Desch; Gerhard Schuler; Hans R Figulla; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2015-02-27       Impact factor: 5.460

Review 2.  Phagocytosis of apoptotic cells: a matter of balance.

Authors:  C J G de Almeida; R Linden
Journal:  Cell Mol Life Sci       Date:  2005-07       Impact factor: 9.261

3.  Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry.

Authors:  David D Berg; Christopher F Barnett; Benjamin B Kenigsberg; Alexander Papolos; Carlos L Alviar; Vivian M Baird-Zars; Gregory W Barsness; Erin A Bohula; Joseph Brennan; James A Burke; Anthony P Carnicelli; Sunit-Preet Chaudhry; Paul C Cremer; Lori B Daniels; Andrew P DeFilippis; Daniel A Gerber; Christopher B Granger; Steven Hollenberg; James M Horowitz; James D Gladden; Jason N Katz; Ellen C Keeley; Norma Keller; Michael C Kontos; Patrick R Lawler; Venu Menon; Thomas S Metkus; P Elliott Miller; Jose Nativi-Nicolau; L Kristin Newby; Jeong-Gun Park; Nicholas Phreaner; Robert O Roswell; Steven P Schulman; Shashank S Sinha; R Jeffrey Snell; Michael A Solomon; Jeffrey J Teuteberg; Wayne Tymchak; Sean van Diepen; David A Morrow
Journal:  Circ Heart Fail       Date:  2019-11-11       Impact factor: 8.790

4.  Percutaneous Mechanical Circulatory Support for Cardiogenic Shock.

Authors:  Kevin J Morine; Navin K Kapur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-01

Review 5.  [Cardiogenic shock : Current evidence].

Authors:  H Thiele
Journal:  Herz       Date:  2017-12       Impact factor: 1.443

Review 6.  Vasopressors for acute myocardial infarction complicated by cardiogenic shock.

Authors:  R Prondzinsky; K Hirsch; L Wachsmuth; M Buerke; S Unverzagt
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-12-04       Impact factor: 0.840

Review 7.  Percutaneous support of the failing left and right ventricle-recommendations for the use of mechanical device therapy.

Authors:  Sven Möbius-Winkler; Michael Fritzenwanger; Rüdiger Pfeifer; P Christian Schulze
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 8.  Interventional therapies in acute myocardial infarction complicated by cardiogenic shock.

Authors:  S de Waha; S Desch; G Fuernau; J Pöss; J Ledwoch; A Jobs; I Eitel; H Thiele
Journal:  Herz       Date:  2017-02       Impact factor: 1.443

Review 9.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

Review 10.  Management of cardiogenic shock complicating myocardial infarction.

Authors:  Alexandre Mebazaa; Alain Combes; Sean van Diepen; Alexa Hollinger; Jaon N Katz; Giovanni Landoni; Ludhmila Abrahao Hajjar; Johan Lassus; Guillaume Lebreton; Gilles Montalescot; Jin Joo Park; Susanna Price; Alessandro Sionis; Demetris Yannopolos; Veli-Pekka Harjola; Bruno Levy; Holger Thiele
Journal:  Intensive Care Med       Date:  2018-05-16       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.